MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
Abstract Background Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular heterogeneity, the purpose of the present study was...
Main Authors: | Hanne Due, Rasmus Froberg Brøndum, Ken H. Young, Martin Bøgsted, Karen Dybkær |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-6643-8 |
Similar Items
-
Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
by: Kasper Thystrup Karstensen, et al.
Published: (2020-12-01) -
The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms
by: Somayeh Yazdanparast, et al.
Published: (2022-06-01) -
Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report
by: Shruthi, et al.
Published: (2023-01-01) -
The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
by: Hikmat Abdel-Razeq, et al.
Published: (2021-05-01) -
Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)